The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...
An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...
Medical Xpress on MSN5d
New drug ataciguat may reduce need for aortic valve surgeries by slowing disease progression: StudyAortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.
Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...
Ataciguat, a novel anthranilic acid derivative, may safely slow progression of valve calcification and potentially delay the need for intervention in patients with fibrocalcific aortic valve stenosis, ...
Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...
An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...
Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback